These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 29546599)

  • 21. Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China.
    Guo N; Cao Y; Dai H; Yuan L; Shi L; Zhang Y
    Med Sci Monit; 2019 Dec; 25():9364-9368. PubMed ID: 31813930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
    Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
    Fervenza FC; Canetta PA; Barbour SJ; Lafayette RA; Rovin BH; Aslam N; Hladunewich MA; Irazabal MV; Sethi S; Gipson DS; Reich HN; Brenchley P; Kretzler M; Radhakrishnan J; Hebert LA; Gipson PE; Thomas LF; McCarthy ET; Appel GB; Jefferson JA; Eirin A; Lieske JC; Hogan MC; Greene EL; Dillon JJ; Leung N; Sedor JR; Rizk DV; Blumenthal SS; Lasic LB; Juncos LA; Green DF; Simon J; Sussman AN; Philibert D; Cattran DC;
    Nephron; 2015; 130(3):159-68. PubMed ID: 26087670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
    Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
    Front Immunol; 2021; 12():738788. PubMed ID: 34721403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor.
    Jatem Escalante E; Segarra Medrano A; Carnicer Cáceres C; Martín-Gómez MA; Salcedo Allende MT; Ostos Roldan H; Agraz Pamplona I
    Nefrologia; 2015; 35(5):479-86. PubMed ID: 26306972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.
    Provatopoulou S; Kalavrizioti D; Stangou M; Kouri MN; Kalliakmani P; Papasotiriou M; Papachristou E; Goumenos DS; Papagianni A
    Rom J Intern Med; 2019 Jun; 57(2):141-150. PubMed ID: 30864406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
    Lu W; Gong S; Li J; Luo H; Wang Y
    Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathological Features of Idiopathic Membranous Nephropathy in 33 Adolescents.
    Li C; Li H; Wen YB; Li JN; Lin WF; Cai JF; Duan L; Li Y; Li XM; Li XW
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):544-551. PubMed ID: 28877834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.
    Guerry MJ; Vanhille P; Ronco P; Debiec H
    Kidney Int; 2016 Jun; 89(6):1399. PubMed ID: 27181779
    [No Abstract]   [Full Text] [Related]  

  • 30. Fibrinogen-albumin ratio predicts treatment response in phospholipase A2 receptor-associated membranous nephropathy with nephrotic syndrome.
    Duan S; Chen S; Chen C; Lu F; Pan Y; Lu Y; Li Q; Liu S; Zhang B; Mao H; Xing C; Yuan Y
    Ren Fail; 2024 Dec; 46(1):2359024. PubMed ID: 38832491
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.
    Li C; Li H; Wen YB; Li XM; Li XW
    BMC Nephrol; 2018 Dec; 19(1):354. PubMed ID: 30541581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.
    Brenchley PE
    J Am Soc Nephrol; 2015 Oct; 26(10):2308-11. PubMed ID: 25804283
    [No Abstract]   [Full Text] [Related]  

  • 33. Plasma exchange and rituximab treatments in primary membranous nephropathy combined with crescentic glomerulonephritis: A case report.
    Lu H; Cui Z; Zhou XJ; Jin QZ; Yu XJ; Wang SX; Wang Y; Zhou FD; Zhao MH
    Medicine (Baltimore); 2019 May; 98(18):e15303. PubMed ID: 31045764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
    Fervenza FC; Appel GB; Barbour SJ; Rovin BH; Lafayette RA; Aslam N; Jefferson JA; Gipson PE; Rizk DV; Sedor JR; Simon JF; McCarthy ET; Brenchley P; Sethi S; Avila-Casado C; Beanlands H; Lieske JC; Philibert D; Li T; Thomas LF; Green DF; Juncos LA; Beara-Lasic L; Blumenthal SS; Sussman AN; Erickson SB; Hladunewich M; Canetta PA; Hebert LA; Leung N; Radhakrishnan J; Reich HN; Parikh SV; Gipson DS; Lee DK; da Costa BR; Jüni P; Cattran DC;
    N Engl J Med; 2019 Jul; 381(1):36-46. PubMed ID: 31269364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phospholipase-A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy.
    Xiao C; Liu Y; Zhang X; Luo L; Li X; Wang T; Tian Z; Qin X; Liu J
    J Clin Lab Anal; 2020 Sep; 34(9):e23368. PubMed ID: 32449206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclical cyclophosphamide and steroids is effective in resistant or relapsing nephrotic syndrome due to M-type phospholipase A2 receptor-related membranous nephropathy after tacrolimus therapy.
    Ramachandran R; Kumar V; Jha V
    Kidney Int; 2016 Jun; 89(6):1401-2. PubMed ID: 27181781
    [No Abstract]   [Full Text] [Related]  

  • 37. Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy.
    Teisseyre M; Perrochia H; Reboul P; Cariou S; Renaud S; Aglae C; Moranne O
    BMC Nephrol; 2020 May; 21(1):196. PubMed ID: 32448215
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pregnancy in a Patient With Primary Membranous Nephropathy and Circulating Anti-PLA2R Antibodies: A Case Report.
    Al-Rabadi L; Ayalon R; Bonegio RG; Ballard JE; Fujii AM; Henderson JM; Salant DJ; Beck LH
    Am J Kidney Dis; 2016 May; 67(5):775-8. PubMed ID: 26744127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
    van den Brand JAJG; Ruggenenti P; Chianca A; Hofstra JM; Perna A; Ruggiero B; Wetzels JFM; Remuzzi G
    J Am Soc Nephrol; 2017 Sep; 28(9):2729-2737. PubMed ID: 28487395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of rituximab in patients with idiopathic membranous nephropathy: a case series and literature review.
    Jeon SJ; Kim JH; Noh HW; Lee GY; Lim JH; Jung HY; Cho JH; Choi JY; Kim CD; Kim YL; Park SH
    Korean J Intern Med; 2022 Jul; 37(4):830-840. PubMed ID: 35421909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.